Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
A European firm with significant operations in the UK, Norgine has invested considerable resources in preparing for Brexit. With less than three weeks to go before the UK is scheduled to leave the EU, chief operating officer Peter Martin is very concerned about the risks of a no-deal Brexit, and the lack of clarity on what will happen next.
With UK biotech venture capital investment at its highest level to date, biotech company building is showing no let up, with almost half of all UK biotech companies formed within the last three years.
Latest From Brexit
Has the European Commission done enough to allow UK-certified medical devices to continue on the EU27 market in the event of the UK dropping out of the EU without a deal – a possibility that remains very real?
How many notified bodies have been designated under the new EU Medical Device and IVD Regulations? Medtech Insight looks at the Nando database to monitor developments.
Dr Jonathan Atkinson, partner at the UK-based intellectual property law firm HGF Ltd, sums up key expectations around legal, patent-related and trademark aspects for pharma in the event of a "no-deal" Brexit, and highlights regulatory changes that could have a bearing on the deal value of UK-bound M&A activity.
March 2019 was a busy month in terms of news for those preparing for the implementation of the MDR and IVDR, while Brexit negotiations spiraled into a new level of madness.
The chief medical and pharmaceutical officers of Scotland have outlined steps being taken to mitigate potential drug shortages if the UK leaves the EU without a deal. Meanwhile, a judge has dismissed a legal challenge to the UK government’s proposal allowing pharmacists to change a doctor’s prescription in the event of a serious medicine shortage.
UK parliament’s indecision over how – or if – to enact Brexit saw the planned March 29 withdrawal deadline come and go. The default positions of the inter-ministerial Office for Lifesciences (OLS) and health-care products regulator (MHRA) are still to prepare for a no-deal exit from the EU.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.